dog |
LD50 |
oral |
> 1600mg/kg (1600mg/kg) |
BEHAVIORAL: FOOD INTAKE (ANIMAL)
GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" |
Chemotherapy Vol. 32(Suppl, |
monkey |
LD50 |
oral |
> 1600mg/kg (1600mg/kg) |
BEHAVIORAL: FOOD INTAKE (ANIMAL)
GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" |
Chemotherapy Vol. 32(Suppl, |
mouse |
LD50 |
intraperitoneal |
3600mg/kg (3600mg/kg) |
? |
Ensho. Japanese Journal of Inflammation. Vol. 11, Pg. 343, 1991. |
mouse |
LD50 |
intravenous |
327mg/kg (327mg/kg) |
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
BEHAVIORAL: ATAXIA
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD |
Chemotherapy Vol. 32(Suppl, |
mouse |
LD50 |
oral |
> 4gm/kg (4000mg/kg) |
? |
European Patent Application. Vol. #0009425, |
mouse |
LD50 |
subcutaneous |
1100mg/kg (1100mg/kg) |
? |
"Current Chemotherapy and Infectious Diseases, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 1979," Washington, DC, American Soc. for Microbiology, 1980Vol. 1, Pg. 456, 1980. |
rat |
LD50 |
intravenous |
236mg/kg (236mg/kg) |
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
BEHAVIORAL: ATAXIA |
Chemotherapy Vol. 32(Suppl, |
rat |
LD50 |
oral |
> 5gm/kg (5000mg/kg) |
? |
Chemotherapy Vol. 32(Suppl, |
rat |
LD50 |
subcutaneous |
> 2gm/kg (2000mg/kg) |
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: ATAXIA
SKIN AND APPENDAGES (SKIN): HAIR: OTHER |
Chemotherapy Vol. 32(Suppl, |